Research Papers:

Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis—a case control study

Claire Decoster, Marine Gilabert, Aurélie Autret, Olivier Turrini, Sandrine Oziel-Taieb, Flora Poizat, Marc Giovannini, Patrice Viens, Juan Iovanna and Jean-Luc Raoul _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:45649-45655. https://doi.org/10.18632/oncotarget.9861

Metrics: PDF 1858 views  |   HTML 3876 views  |   ?  


Claire Decoster1, Marine Gilabert1, Aurélie Autret1,2, Olivier Turrini3, Sandrine Oziel-Taieb1, Flora Poizat4, Marc Giovannini1, Patrice Viens1, Juan Iovanna5, Jean-Luc Raoul1

1Department of Medical Oncology, Paoli-Calmettes Institute, Marseille 13273, France

2Biostatistic Unit, Paoli-Calmettes Institute, Marseille 13273, France

3Department of Digestive Surgery, Paoli-Calmettes Institute, Marseille 13273, France

4Department of Pathology, Paoli-Calmettes Institute, Marseille 13273, France

5Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS UMR 7258, Aix-Marseille University and Paoli-Calmettes Institute, Marseille 13273, France

Correspondence to:

Raoul Jean-Luc, email: [email protected]

Keywords: pancreatic adenocarcinoma, lung metastases, prognosis, overall survival, local evolution

Received: November 11, 2015     Accepted: May 08, 2016     Published: June 06, 2016


The prognosis of metastatic pancreatic ductal adenocarcinoma (PDAC) is grim, with a median overall survival of under 1 year. In our clinical practice, we observed a few cases of isolated lung metastases from PDAC with unusually long outcomes. We compared these cases in a case-control study of lung-only vs. liver-only metastases from PDAC.

From our database, we found 37 cases of lung-only metastases and paired them with 37 cases of liver-only metastases by age, tumor location and treatment.

The lung-only group differed significantly from the liver-only group with respect to the following parameters: female predominance, more metachronous cases, fewer nodules per patient, and smaller increases in tumor markers. Local invasion parameters (i.e., arterial or venous involvement) were not significantly different. The outcomes were significantly different, with a median overall survival from the occurrence of metastases of 20.8 vs. 9.1 months and a median progression-free survival of 11 vs. 3.5 months.

In conclusion, this case-control study seemed to confirm that lung-only PDAC metastases have prognoses different from those of liver-only metastases. A better understanding of the mechanisms underlying these differences will help identify abnormalities associated with tumor aggressiveness.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9861